Dermofunctional Vehicle Downregulates LL-37 and MMPs and Upregulates IGFBP-3

Area of Science:

• Dermatology
• Immunology
• Biochemistry

Background:

• Functional dermatological bases can actively modulate skin homeostasis.
• Cleoderm™ is a dermofunctional base with anti-inflammatory, antioxidant, and barrier-supportive properties, featuring a patented *Cleome gynandra* extract, palmitoyl tripeptide-8, bisabolol, hyaluronic acid, and functional oils.

Purpose of the Study:

• To evaluate the immunomodulatory and matrix-protective effects of Cleoderm™ in a skin co-culture model.
• To identify key biomarkers modulated by Cleoderm™ with relevance to acne and rosacea.

Main Methods:

• A human keratinocyte and fibroblast co-culture model was used.
• Cleoderm™ was tested at non-cytotoxic concentrations (1.0% and 10.0%) with or without LPS stimulation.
• Cytokine and matrix metalloproteinase (MMP) levels were quantified using ELISA and RT-qPCR, while protein levels of LL-37, IGFBP-3, and TGF-β were assessed via Western blot.

Main Results:

• Cleoderm™ exhibited no cytotoxicity up to 10%.
• It significantly reduced pro-inflammatory mediators (IL-6, TNF-α) and MMPs (MMP-1, -3, -13), while increasing anti-inflammatory cytokines (IL-10, TGF-β).
• Cleoderm™ modulated LL-37 and IGFBP-3 levels, suggesting potential benefits for sebaceous lipogenesis and immune regulation.

Conclusions:

• Cleoderm™ acts as an active dermofunctional base, tempering inflammation and preserving extracellular matrix integrity.
• It modulates key biomarkers (LL-37, IGFBP-3) relevant to acne and rosacea.
• Findings support Cleoderm™'s use as a biologically supportive base for personalized skincare and warrant clinical evaluation.